Sharemaestro company-news research for Commercial Metals Company (CMC), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Measured evidence
Company news sentiment
CMC news sentiment
Commercial Metals Company
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone53Neutral is 50
Balanced news tone
78/100 evidence confidence
100% direct company focus
8 current stories across 3 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 8 fresh independent stories, including 8 company-specific items across 3 publishers.
Latest source headline Inovio (INO) Q2 2026 Earnings Call Transcript nasdaq.com · 13 Aug 2026 00:58What supports the read
8 current stories are mapped specifically to CMC.
The read spans 3 publishers rather than depending on one outlet.
Cross-story agreement is 84/100, indicating a comparatively coherent tape.
What tempers the read
Price is moving more forcefully than the current news tone suggests.
53/100
Weighted toneBalanced news tone
78/100
Evidence confidencesolid confidence
100%/100
Company focus8 direct stories
84/100
Evidence agreement16/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth90
7.18 effective storiesSource breadth60
3 independent publishersDirect relevance100
company-specific evidence shareFreshness76
recency-weighted evidenceAgreement84
cross-story consistencySource independence64
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings546 stories · 75%
Deals and strategy581 stories · 12%
Guidance571 stories · 12%
Source mix
Where the evidence comes from
nasdaq.com583 stories · 38%
finance.yahoo.com573 stories · 38%
seekingalpha.com432 stories · 25%
Recurring subjects
Subjects appearing most often
Earnings6Financial Results4Fda Approval4Clinical Trials4Free Cash Flow3Biotech3Balance Sheet3Fourth Quarter2Earnings Per Share2Revenue Growth1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#138Tone
nasdaq.comDirect company coverage
Inovio (INO) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Director of Communications - Jennie WillsonPresident and Chief Executive Officer - Dr. Jacqueline E. SheaChief Medical Officer - Dr. Michael SumnerChief Commercial Officer - Steven EggeChief Financial Officer - Peter D. Kies TAKEAWAYS INO-3107 PDUFA Date -- Oct. 30, 2026, for the Inovio Pharmaceuticals, Inc.(NASDAQ:INO) Biologics License Application (BLA), representing the target action date for regulatory review.Cash and Cash Equivalents -- $36.7 million as of June 30, 2026, a decrease from $58.5 mi
Balance SheetBiotechClinical TrialsEarningsFda ApprovalFinancial Results
- Published
- 13 Aug 2026 00:58
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#258Tone
finance.yahoo.comDirect company coverage
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J., Aug. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the
AcquisitionFda ApprovalGene TherapyM ARare DiseasesRevenue Growth
- Published
- 12 Aug 2026 20:01
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#353Tone
seekingalpha.comDirect company coverage
Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026
Earnings Call Insights: Taysha Gene Therapies (TSHA) Q2 2026 MANAGEMENT VIEW * "The second quarter of 2026 was a highly productive period for Taysha," said CEO Sean Nolan, highlighting "the completion of dosing in both the REVEAL pivotal and ASPIRE trials" and progress "toward a potential BLA submission for TSHA-102." (CEO & Chairman Sean Nolan) * Nolan said the REVEAL pivotal trial was "over-enrolled" with "a total of 17 patients dosed with TSHA-102" and described the age mix as "reflective of the broader Rett syndrome population," which he said "may support a broad label for TSHA-102." (CEO
BiotechClinical TrialsEarningsFda ApprovalFourth QuarterRegulation
- Published
- 12 Aug 2026 01:38
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#470Tone
nasdaq.comDirect company coverage
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Monday, Aug. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer - Thomas LeggettChief Executive Officer - Ian SmithChief Medical Officer - Barry TichoChief Patient Officer - Jason Hoitt Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Phase III Enrollment -- 162 patients, representing completion of the primary analysis population for the U.S., U.K., and Japan as of June 2026.EMPEROR Study Progress -- 145 patients through week 8 of treatment, including receipt of two 70 milligram loading doses of zorevunersen or a sham contr
Balance SheetClinical TrialsDravet SyndromeFda ApprovalFinancial ResultsMarkets
- Published
- 11 Aug 2026 01:58
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#554Tone
finance.yahoo.comDirect company coverage
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
ProKidney Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth Locke as Chief Technical Officer, adding more than 25 years of R&D, CMC and supply chain leadership experience Ended Q2 2026 with $181.6 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- P
BiotechChronic Kidney DiseaseClinical TrialsEarningsFinancial Results
- Published
- 10 Aug 2026 20:05
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#631Tone
seekingalpha.comDirect company coverage
Hormuz risk premium: Who wins and loses in the tanker trade
[The tanker] Dikuch/iStock via Getty Images INVESTORS SHOULD KNOW: The Strait of Hormuz remains a live flashpoint for global oil markets, with Iran-Oman shipping talks nearing completion but full reopening still tied to unresolved U.S.-Iran demands. This keeps risk premiums embedded in tanker rates, pipeline economics, and crude logistics across the energy sector. BACKGROUND The Strait of Hormuz is the world's most critical oil chokepoint, with roughly one-fifth of global oil and LNG shipments transiting the waterway. Its partial or full closure has direct consequences for tanker rates, midstr
EarningsEarnings GrowthEnergyFree Cash FlowGeopolitical RiskMidstream
- Published
- 10 Aug 2026 18:25
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#757Tone
finance.yahoo.comDirect company coverage
Koppers Q2 Earnings Call Highlights
Key Points Interested in Koppers Holdings Inc.? Here are five stocks we like better. Koppers lowered its 2026 adjusted EBITDA outlook to $240 million–$250 million from ongoing cost pressures, particularly higher coal tar, freight and logistics costs in Carbon Materials and Chemicals. The company maintained its sales forecast of $1.9 billion–$2 billion. Second-quarter sales increased 3% to $520 million, but adjusted EBITDA fell 7.9% to $71 million. Performance Chemicals delivered strong growth, while RUPS and Carbon Materials and Chemicals experienced profitability declines. Koppers generated r
Cost PressuresDebt ReductionDividendsEarningsEarnings Per ShareFree Cash Flow
- Published
- 08 Aug 2026 15:03
- Catalyst
- Guidance
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#887Tone
nasdaq.comDirect company coverage
Anika (ANIK) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stephen D. GriffinSenior Vice President, Chief Accounting Officer, and Treasurer - Ian W. McLeodExecutive Director, Corporate Development and Investor Relations - Matthew Hall TAKEAWAYS Total Revenue -- $32.6 million, an increase of 16% reflecting record performance in the commercial channel and strength in OEM sales.Commercial Channel Revenue -- $13.9 million, growing 17% year over year and representing the strongest quarterly performance in company history.In
Balance SheetEarningsEarnings Per ShareFinancial ResultsFourth QuarterFree Cash Flow
- Published
- 08 Aug 2026 01:00
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.